Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib

Lung, Respiratory and Thoracic CancerLymphoma

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Lancet Oncol.

Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E

doi: 10.1016/S1470-

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Lancet Oncol.

Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT

doi: 10.1016/

Lung, Respiratory and Thoracic CancerLymphoma

Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

JAMA Oncol.

Hung YP, Dong F, Watkins JC, Nardi V, Bueno R, Dal Cin P, Godleski JJ, Crum CP, Chirieac LR

doi: 10.1001/

Lymphoma

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients

Front Oncol.

Britschgi C, Addeo A, Rechsteiner M, Delaloye R, Früh M, Metro G, Banini M, Gautschi O, Rothschild SI, Wild PJ, Banna GL, Curioni-Fontecedro A

doi: 10.3389/fonc.2020.01299.

Lung, Respiratory and Thoracic Cancer

Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer

J Thorac Oncol.

Nishio M, Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, Mok T, Scagliotti GV, Spigel DR, Viraswami-Appanna K, Chen Z, Passos VQ, Shaw AT

doi: 10.1016/j.jtho.2019.11.006.

Lung, Respiratory and Thoracic CancerLymphoma

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

J Thorac Oncol.

Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M

doi: 10.1016/

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-positive NSCLC: Pooled Analysis of Two Prospective Trials

J Thorac Oncol.

Noé J, Lovejoy A, Ignatius Ou SH, Yaung SJ, Bordogna W, Klass DM, Cummings CA, Shaw AT

doi: 10.1016/j.jtho.2019.10.015.

Lung, Respiratory and Thoracic Cancer

The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis

Oncologist.

O'Kane GM, Su J, Tse BC, Tam V, Tse T, Lu L, Borean M, Tam E, Labbé C, Naik H, Mittmann N, Doherty MK, Bradbury PA, Leighl NB, Shepherd FA, Richard NM, Edelstein K, Shultz D, Brown MC, Xu W, Howell D, Liu G

doi: 10.1634/theoncologist.

Lung, Respiratory and Thoracic Cancer

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study

J Thorac Oncol.

Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ou SI, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT

doi: 10.1016/j.jtho.2020.10.007.

Related content

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients

Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-positive NSCLC: Pooled Analysis of Two Prospective Trials

The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study